Changes in the use patterns of bDMARDs in patients with rheumatic diseases over the past 13 years

Abstract The better understanding of the safety of biologic DMARDs (bDMARDs), as well as the emergence of new bDMARDs against different therapeutic targets and biosimilars have likely influenced the use patterns of these compounds over time. The aim of this study is to assess changes in demographic...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Carlos Sánchez-Piedra, Diana Sueiro-Delgado, Javier García-González, Inmaculada Ros-Vilamajo, Agueda Prior-Español, Manuel José Moreno-Ramos, Blanca Garcia-Magallon, Jerusalen Calvo-Gutiérrez, Yanira Perez-Vera, Raquel Martín-Domenech, Dolores Ruiz-Montesino, Paloma Vela-Casasempere, Lorena Expósito, Fernando Sánchez-Alonso, Enrique González-Davila, Federico Díaz-González
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
R
Q
Acceso en línea:https://doaj.org/article/c21d7032e4634106a34eddf55c0f0d5e
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:c21d7032e4634106a34eddf55c0f0d5e
record_format dspace
spelling oai:doaj.org-article:c21d7032e4634106a34eddf55c0f0d5e2021-12-02T16:26:38ZChanges in the use patterns of bDMARDs in patients with rheumatic diseases over the past 13 years10.1038/s41598-021-94504-x2045-2322https://doaj.org/article/c21d7032e4634106a34eddf55c0f0d5e2021-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-94504-xhttps://doaj.org/toc/2045-2322Abstract The better understanding of the safety of biologic DMARDs (bDMARDs), as well as the emergence of new bDMARDs against different therapeutic targets and biosimilars have likely influenced the use patterns of these compounds over time. The aim of this study is to assess changes in demographic characteristics, disease activity and treatment patterns in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) who started a first- or second-line biologic between 2007 and mid-2020. Patients diagnosed with RA, PsA or AS included in the BIOBADASER registry from January 2007 to July 2020 were included. According to the start date of a first- or second-line biologic therapy, patients were stratified into four time periods: 2007–2009; 2010–2013; 2014–2017; 2018–2020 and analyzed cross-sectionally in each period. Demographic and clinical variables, as well as the type of biologic used, were assessed. Generalized linear models were applied to study the evolution of the variables of interest over time periods, the diagnosis, and the interactions between them. A total of 4543 patients initiated a first biologic during the entire time frame of the study. Over the four time periods, disease evolution at the time of biologic initiation (p < 0.001), disease activity (p < 0.001), retention rate (p < 0.001) and the use of tumor necrosis factor inhibitors as a first-line treatment (p < 0.001) showed a significant tendency to decrease. Conversely, comorbidities, as assessed by the Charlson index (p < 0.001), and the percentage of patients using bDMARDs in monotherapy (p < 0.001), and corticosteroids (p < 0.001) tended to increase over time. Over the entire period of the study's analysis, 3289 patients started a second biologic. The following trends were observed: decreased DAS28 at switching (p < 0.001), lower retention rates (p = 0.004), and incremental changes to the therapeutic target between the first and second biologic (p < 0.001). From 2007 until now rheumatic patients who started a biologic were older, exhibited less clinical activity, presented more comorbidities, and switched to a different biologic more frequently and earlier.Carlos Sánchez-PiedraDiana Sueiro-DelgadoJavier García-GonzálezInmaculada Ros-VilamajoAgueda Prior-EspañolManuel José Moreno-RamosBlanca Garcia-MagallonJerusalen Calvo-GutiérrezYanira Perez-VeraRaquel Martín-DomenechDolores Ruiz-MontesinoPaloma Vela-CasasempereLorena ExpósitoFernando Sánchez-AlonsoEnrique González-DavilaFederico Díaz-GonzálezNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Carlos Sánchez-Piedra
Diana Sueiro-Delgado
Javier García-González
Inmaculada Ros-Vilamajo
Agueda Prior-Español
Manuel José Moreno-Ramos
Blanca Garcia-Magallon
Jerusalen Calvo-Gutiérrez
Yanira Perez-Vera
Raquel Martín-Domenech
Dolores Ruiz-Montesino
Paloma Vela-Casasempere
Lorena Expósito
Fernando Sánchez-Alonso
Enrique González-Davila
Federico Díaz-González
Changes in the use patterns of bDMARDs in patients with rheumatic diseases over the past 13 years
description Abstract The better understanding of the safety of biologic DMARDs (bDMARDs), as well as the emergence of new bDMARDs against different therapeutic targets and biosimilars have likely influenced the use patterns of these compounds over time. The aim of this study is to assess changes in demographic characteristics, disease activity and treatment patterns in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) who started a first- or second-line biologic between 2007 and mid-2020. Patients diagnosed with RA, PsA or AS included in the BIOBADASER registry from January 2007 to July 2020 were included. According to the start date of a first- or second-line biologic therapy, patients were stratified into four time periods: 2007–2009; 2010–2013; 2014–2017; 2018–2020 and analyzed cross-sectionally in each period. Demographic and clinical variables, as well as the type of biologic used, were assessed. Generalized linear models were applied to study the evolution of the variables of interest over time periods, the diagnosis, and the interactions between them. A total of 4543 patients initiated a first biologic during the entire time frame of the study. Over the four time periods, disease evolution at the time of biologic initiation (p < 0.001), disease activity (p < 0.001), retention rate (p < 0.001) and the use of tumor necrosis factor inhibitors as a first-line treatment (p < 0.001) showed a significant tendency to decrease. Conversely, comorbidities, as assessed by the Charlson index (p < 0.001), and the percentage of patients using bDMARDs in monotherapy (p < 0.001), and corticosteroids (p < 0.001) tended to increase over time. Over the entire period of the study's analysis, 3289 patients started a second biologic. The following trends were observed: decreased DAS28 at switching (p < 0.001), lower retention rates (p = 0.004), and incremental changes to the therapeutic target between the first and second biologic (p < 0.001). From 2007 until now rheumatic patients who started a biologic were older, exhibited less clinical activity, presented more comorbidities, and switched to a different biologic more frequently and earlier.
format article
author Carlos Sánchez-Piedra
Diana Sueiro-Delgado
Javier García-González
Inmaculada Ros-Vilamajo
Agueda Prior-Español
Manuel José Moreno-Ramos
Blanca Garcia-Magallon
Jerusalen Calvo-Gutiérrez
Yanira Perez-Vera
Raquel Martín-Domenech
Dolores Ruiz-Montesino
Paloma Vela-Casasempere
Lorena Expósito
Fernando Sánchez-Alonso
Enrique González-Davila
Federico Díaz-González
author_facet Carlos Sánchez-Piedra
Diana Sueiro-Delgado
Javier García-González
Inmaculada Ros-Vilamajo
Agueda Prior-Español
Manuel José Moreno-Ramos
Blanca Garcia-Magallon
Jerusalen Calvo-Gutiérrez
Yanira Perez-Vera
Raquel Martín-Domenech
Dolores Ruiz-Montesino
Paloma Vela-Casasempere
Lorena Expósito
Fernando Sánchez-Alonso
Enrique González-Davila
Federico Díaz-González
author_sort Carlos Sánchez-Piedra
title Changes in the use patterns of bDMARDs in patients with rheumatic diseases over the past 13 years
title_short Changes in the use patterns of bDMARDs in patients with rheumatic diseases over the past 13 years
title_full Changes in the use patterns of bDMARDs in patients with rheumatic diseases over the past 13 years
title_fullStr Changes in the use patterns of bDMARDs in patients with rheumatic diseases over the past 13 years
title_full_unstemmed Changes in the use patterns of bDMARDs in patients with rheumatic diseases over the past 13 years
title_sort changes in the use patterns of bdmards in patients with rheumatic diseases over the past 13 years
publisher Nature Portfolio
publishDate 2021
url https://doaj.org/article/c21d7032e4634106a34eddf55c0f0d5e
work_keys_str_mv AT carlossanchezpiedra changesintheusepatternsofbdmardsinpatientswithrheumaticdiseasesoverthepast13years
AT dianasueirodelgado changesintheusepatternsofbdmardsinpatientswithrheumaticdiseasesoverthepast13years
AT javiergarciagonzalez changesintheusepatternsofbdmardsinpatientswithrheumaticdiseasesoverthepast13years
AT inmaculadarosvilamajo changesintheusepatternsofbdmardsinpatientswithrheumaticdiseasesoverthepast13years
AT aguedapriorespanol changesintheusepatternsofbdmardsinpatientswithrheumaticdiseasesoverthepast13years
AT manueljosemorenoramos changesintheusepatternsofbdmardsinpatientswithrheumaticdiseasesoverthepast13years
AT blancagarciamagallon changesintheusepatternsofbdmardsinpatientswithrheumaticdiseasesoverthepast13years
AT jerusalencalvogutierrez changesintheusepatternsofbdmardsinpatientswithrheumaticdiseasesoverthepast13years
AT yaniraperezvera changesintheusepatternsofbdmardsinpatientswithrheumaticdiseasesoverthepast13years
AT raquelmartindomenech changesintheusepatternsofbdmardsinpatientswithrheumaticdiseasesoverthepast13years
AT doloresruizmontesino changesintheusepatternsofbdmardsinpatientswithrheumaticdiseasesoverthepast13years
AT palomavelacasasempere changesintheusepatternsofbdmardsinpatientswithrheumaticdiseasesoverthepast13years
AT lorenaexposito changesintheusepatternsofbdmardsinpatientswithrheumaticdiseasesoverthepast13years
AT fernandosanchezalonso changesintheusepatternsofbdmardsinpatientswithrheumaticdiseasesoverthepast13years
AT enriquegonzalezdavila changesintheusepatternsofbdmardsinpatientswithrheumaticdiseasesoverthepast13years
AT federicodiazgonzalez changesintheusepatternsofbdmardsinpatientswithrheumaticdiseasesoverthepast13years
_version_ 1718384015169290240